^
No biomarker
Thymic Carcinoma
lenvatinib
Sensitive: A1 - Approval
No biomarker
Thymic Carcinoma
GEM-CAP
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
LV5FU2
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
CaT
Sensitive: A2 - Guideline
KIT mutation
Thymic Carcinoma
sunitinib
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
VIP
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
EP
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
ADOC
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
CAP + prednisone
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
CAP
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
carboplatin
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
ifosfamide
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
etoposide oral
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
prednisone + octreotide
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
octreotide
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
everolimus
Sensitive: A2 - Guideline
No biomarker
Thymic Carcinoma
pemetrexed
Sensitive: A2 - Guideline
EIF4EBP1 expression
Thymic Carcinoma
everolimus
Resistant: C3 – Early Trials
HER-2 positive
Thymic Carcinoma
pyrotinib
Sensitive: C3 – Early Trials
HER-2 mutation
Thymic Carcinoma
pyrotinib
Sensitive: C3 – Early Trials
IGF1R expression
Thymic Carcinoma
everolimus
Resistant: C3 – Early Trials
KIT D820Y
Thymic Carcinoma
sorafenib
Sensitive: C4 – Case Studies
PD-L1 overexpression
Thymic Carcinoma
pembrolizumab
Sensitive: C4 – Case Studies
PD-L1 overexpression
Thymic Carcinoma
pembrolizumab
Resistant: C4 – Case Studies
EGFR exon 20 insertion
Thymic Carcinoma
anlotinib
Sensitive: C4 – Case Studies
EGFR exon 19 deletion
Thymic Carcinoma
icotinib
Sensitive: C4 – Case Studies
MSLN expression
Thymic Carcinoma
BAY 94-9343
Sensitive: D – Preclinical